Rozlytrek (entrectinib) is an oral tumor-agnostic agent intended to selectively inhibit the tyrosine kinase activity of TRKA, TRKB, TRKC, and ROS1 (ROS proto-oncogene 1 receptor tyrosine kinase) rearrangements. Rozlytrek is indicated for the treatment of adult and adolescent patients whose cancers have NTRK (neurotrophic tyrosine receptor kinase) gene fusion, and for whom there are no effective treatments, and for the treatment of adults with metastatic non-small cell lung cancer whose tumors are ROS1 positive.
If you have a Hayes login, click here to view the full report on the Knowledge Center.